GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model
- 5 August 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 129 (2) , 247-253
- https://doi.org/10.1046/j.1365-2249.2002.01929.x
Abstract
SUMMARY: Immune responses towards malignant plasma cells have clearly been demonstrated in the course of monoclonal B cell dyscrasias and shown to be mostly specific for idiotypic determinants of the monoclonal immunoglobulin (Ig). These responses are specifically efficient against lymphoma cells expressing a membrane form of the monoclonal Ig. In myeloma, such immune responses are often weak and a number of strategies are currently assayed in order to boost the cell-mediated responses against the secreted monoclonal Ig. The use of cytokines promoting Th1 responses could be helpful for the induction of anti-tumour immunity and the control of residual disease in patients treated with myeloablative therapy, and such strategies need to be evaluated.In a light chain myeloma model where the monoclonal Ig can only be secreted, we tried to induce protective immune responses through immunization of animals with transfected malignant plasma cells. An expression plasmid encoding GM-CSF and IL-12 proved to be highly efficient for the induction of both cytotoxic and proliferative responses after immunization of animals with transfected and irradiated tumour cells. Anti-tumour immunization according to this protocol was successful in protecting 93·4% of the animals against a subsequent tumour challenge.Keywords
This publication has 23 references indexed in Scilit:
- Light chain myeloma plasma cells induce a strong cell-mediated immune response mainly directed against the monoclonal light chain determinants in a murine experimental modelCancer Immunology, Immunotherapy, 2002
- Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathwayBritish Journal of Haematology, 2001
- Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myelomaBone Marrow Transplantation, 2000
- Idiotype Immunity (Natural and Vaccine-induced) in Early Stage Multiple MyelomaActa Oncologica, 2000
- Idiotypic protein-pulsed dendritic cell vaccination in multiple myelomaInternational Journal of Cancer, 1999
- Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte–macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunityGene Therapy, 1998
- Idiotypic vaccination in B-cell malignanciesMolecular Medicine Today, 1997
- Role of Interferon-γ in Mediating the Antitumor Efficacy of Interleukin-12Journal of Immunotherapy, 1995
- Helper T cell recognition of the variable domains of a mouse myeloma protein (315). Effect of the major histocompatibility complex and domain conformation.The Journal of Experimental Medicine, 1982
- Myeloma Proteins as Tumor-Specific Transplantation AntigensProceedings of the National Academy of Sciences, 1972